EMEA-001410-PIP02-17-M04

Table of contents

Key facts

Invented name
Ninlaro
Active substance
Ixazomib
Therapeutic area
Oncology
Decision number
P/0237/2022
PIP number
EMEA-001410-PIP02-17-M04
Pharmaceutical form(s)
  • Powder for solution for injection or infusion
  • Capsule, hard
Condition(s) / indication(s)
  • Treatment of lymphoid malignancies (excluding multiple myeloma)
  • Treatment of multiple myeloma
Route(s) of administration
  • Intravenous use
  • Oral use
  • Gastric use
Contact for public enquiries
Takeda Pharm A/S

E-mail: medinfoEMEA@takeda.com​
Tel. +44 (0)3333 000181
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating